2. Academic Validation
  3. Structure-Based Discovery of Potent and Selective Small-Molecule α5β1 Integrin Inhibitors for Asthma Therapy

Structure-Based Discovery of Potent and Selective Small-Molecule α5β1 Integrin Inhibitors for Asthma Therapy

  • ACS Omega. 2025 Dec 4;10(49):60970-60992. doi: 10.1021/acsomega.5c10068.
Richard Beresis 1,  Aparna Sundaram 2,  Hyunil Jo 1,  Marc Adler 3,  Zheng Wang 4,  Joel McIntosh 5,  Seul Ki Yeon 1,  Qiuya Huang 4,  Grace Ngo 2,  Dean Sheppard 2,  William F DeGrado 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.
  • 2 Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, California 94143, United States.
  • 3 ChemPartner-San Francisco, 280 Utah Avenue, South San Francisco, California 94080, United States.
  • 4 ChemPartner-Chengdu, Tianfu Life Science Park, No. 88, Keyuan South Road, Hi-Tech Zone, Chengdu, Sichuan 610041, China.
  • 5 Nurix Inc, San Francisco, California 94158, United States.
PMID: 41427225 DOI: 10.1021/acsomega.5c10068
Abstract

Integrin α5β1 is the principal fibronectin-binding Integrin in airway smooth muscle (ASM), and its modulation attenuates airway narrowing induced by asthmagenic cytokines in mouse models of allergic asthma. These findings highlight small molecule α5β1 inhibition as a promising therapeutic strategy. Although inhalation is the preferred route for asthma therapy, previously reported α5β1 antagonists lacked sufficient potency, selectivity, or inhalation pharmacokinetic data. Here, we report a potent series of α5β1 inhibitors identified through structure-based design and sequential optimization. Lead compound 65 demonstrates subnanomolar cellular potency, high selectivity over Other integrins, and favorable rodent pharmacokinetics following inhalation dosing. These attributes support its potential as a once-daily inhaled therapy for asthma. Collectively, our results establish selective α5β1 inhibition by inhalation as a novel approach to reduce ASM tension through the disruption of cellular tethering.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z